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cured by multimodal treatment. Genetically, about 10–20% of all 
CRC cases develop on a familiar background of mismatch repair 
deficiency, whereas the majority of CRCs develop sporadically. 
The prognosis of patients with CRC depends on the tumor stage 
(Union Internationale Contre le Cancer, UICC). The current 
guidelines use tumor stage, grade and other risk factors, such as 
emergency surgery for primary disease, and perforation, to define 
treatment indications for adjuvant chemotherapy in stage II and III 
disease.
We know that the prognosis of CRC patients is strongly influ-
enced by tumor-host interactions reflected by T cell infiltrates in 
primary tumors and metastatic lesions [1, 2]. Although T cell den-
sities in the primary tumor represent a strong prognostic marker 
and T cell densities at the invasive margin of metastatic lesions 
constitute a strong predictive marker for chemotherapy response, 
the analysis of T cell infiltrates is not as yet part of routine diagnos-
tic work up.
Current immunotherapies typically rely on the activation of T 
cells in this microenvironment. Immunotherapy using checkpoint 
inhibitors such as antibodies directed against cytotoxic T lympho-
cyte antigen-4 (CTLA-4) and programmed cell death protein (PD-
1)/PD-1 receptor (PD-L1) has shown impressive results in mela-
noma, non-small cell lung cancer (NSCLC), renal cancer, bladder 
cancer, Hodgkin’s lymphoma and other tumor types, and is already 
approved as standard treatment in a variety of indications [3–6].
PD-1, also known as CD279, is an inhibitory receptor expressed 
on CD4+ T cells, CD8+ T cells, NKT cells and B cells as well as 
monocytes and macrophages. The natural ligands for PD-1 are 
PD-L1 (B7-H1) and PD-L2 (B7-DC). PD-L1 is expressed on a vari-
ety of immune cells, and is significantly overexpressed in tumors. 
The PD-L1/PD-1 pathway is associated with immune evasion and 
T cell exhaustion, resulting in impaired T cell proliferation, cyto-
kine production and cytotoxicity [7]. 
In CRC, PD-1 is frequently upregulated on tumor-infiltrating 
T cells (TIL) compared to T cells from lymph nodes, and these T 
cells have a decreased ability to produce cytokines and perforin [7]. 
The expression of PD-L1 was shown to be high in the environ-
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Summary
It is known that the immune response, reflected by high 
T cell infiltrates in primary tumors and metastases, influ-
ences the clinical course of colorectal cancer (CRC). 
Therefore, immunotherapy concepts have been adapted 
from other tumor entities, which typically rely on the ac-
tivation of T cells in the tumor microenvironment (e.g. 
blockade of the immune checkpoint molecules PD-1 and 
CTLA-4). However, most of the strategies using the ap-
proved checkpoint inhibitors and/or combination strate-
gies have more or less failed to produce impressive re-
sults in early phase trials in CRC. Therefore, a number of 
novel targets for checkpoint inhibition are currently in 
early phase clinical testing (TIM-3, Lag-3, OX40, GITR, 
4-1BB, CD40, CD70). A simple activation of infiltrating T 
cells will not, however, lead to a meaningful anti-tumor 
response without modulating the environmental factors 
in CRC. Thus, it is absolutely necessary to improve our 
understanding of the complex regulation of the tumor 
microenvironment in CRC to design individual combina-
tion treatments leading to effective immune control.
© 2016 S. Karger GmbH, Freiburg
Currently, colorectal cancer (CRC) is 1 of the 3 most commonly 
diagnosed cancer types in Europe and worldwide. In early stage 
CRC, overall survival rates of more than 70% for localized disease 
are observed. However, almost 50% of all CRC patients are diag-
nosed with metastatic disease or experience recurrent metastatic 
disease after treatment of the initial local disease. The only availa-
ble curative treatment remains surgery for localized disease; in the 
setting of metastatic disease a small proportion of patients can be 
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ment, suggesting that the PD-L1/PD-1 axis plays an important role 
in creating an immunosuppressive environment in CRC. It was 
thought that in CRC anti-PD-1/PD-L1 antibodies might have simi-
lar therapeutic effects to those seen in melanoma or NSCLC, but 
unfortunately early phase trials using PD-1/PD-L1 blockade alone 
failed to induce objective responses in patients with metastatic mis-
match-repair stable (MSS) CRC [8]. In that trial, pembrolizumab 
induced remarkable responses in patients with mismatch-repair 
deficient CRC (MSI). Currently, several ongoing clinical phase II 
and phase III trials are testing PD-1 antibodies in MSI CRC pa-
tients with pretreated and untreated metastatic disease.
CTLA-4 is another inhibiting receptor expressed on T cells and 
other immune cells. CTLA-4 has similar binding affinities for B7-1 
and B7-2, and transmits inhibitory signals. Ipilimumab is the only 
approved monoclonal antibody that targets CTLA-4 and is being 
used as monotherapy or combination therapy in melanoma. 
CTLA-4 antibodies have been shown to deplete regulatory T cells 
(Tregs). The anti-CTLA-4 antibody tremelimumab was tested in a 
phase II trial in refractory metastatic CRC patients without show-
ing any clinical efficacy [9]. Currently, several ongoing trials are 
testing combinations of ipilimumab with PD-1/PD-L1 antibodies 
as well as combinations of different checkpoint inhibitors with 
chemotherapy or radiotherapy in CRC.
A number of novel targets for checkpoint inhibition are cur-
rently in early phase clinical testing. One novel monoclonal anti-
body targeting TIM-3 (T cell immunoglobulin and mucin contain-
ing protein-3) was identified on T cells that express interferon 
(IFN)-γ. The ligand for TIM-3, galactin-9, inhibits Th1 T cell re-
sponses and induces apoptosis [10]. TIM-3-mediated signaling 
 together with PD-1 induces T cell exhaustion. In animal models, 
TIM-3 blockade reinduced potent T cell immunity and synergistic 
effects have been shown for the combination with anti-PD-1. It 
was shown that high TIM-3 and high PD-1 expression on TILs is a 
marker for T cell exhaustion and dysfunction [11]. TILs in CRC 
seem to express higher levels of TIM-3 and PD-1 compared to T 
cells in the adjacent normal tissue, suggesting that TIM-3 repre-
sents a dominant inhibitory receptor on T cells in CRC. The ongo-
ing trials will show if TIM-3 blockade might play a role in CRC 
patients [12].
The lymphocyte activation gene-3 (LAG-3) is a cell surface pro-
tein belonging to the immunoglobulin superfamily. LAG-3 nega-
tively regulates T cell proliferation by interacting with MHC class 
II molecules. LAG-3 is expressed on T cells, NK cells, B cells and 
plasmacytoid dendritic cells (DC) [13]. LAG-3 expression on T 
cells was recognized as one of the markers indicating T cell exhaus-
tion. A subgroup of Tregs also strongly expresses LAG-3. Blocking 
LAG-3 in combination with PD-1 blockade resulted in higher re-
sponse rates in preclinical models [14]. Several ongoing trials are 
testing anti-LAG-3 in monotherapy or combination therapy with 
anti-PD-1 in advanced malignancies.
OX40 (CD134) represents another checkpoint molecule that 
 belongs to the TNF receptor superfamily. OX40 is expressed tran-
siently on activated T cells following activation of the T cell recep-
tor (TCR), and on other cells belonging to the innate immune sys-
tem, such as NK cells, NK-T cells and neutrophils. Stimulation of 
these cells via OX40 results in a pro-inflammatory and pro-survival 
effect. The OX40 ligand (OX40L) is expressed on activated anti-
gen-presenting cells (APCs), activated endothelial cells, epithelial 
cells and B cells. Agonistic OX40 antibodies and soluble forms of 
OX40L have been shown to induce T cell differentiation, survival, 
expansion and cytotoxicity. OX40 antibodies suppress Treg func-
tion. OX40 was shown to be highly expressed on TILs in CRC 
 patients. OX40 agonistic antibodies induce objective responses in 
some patients [15]. However, OX40 agonists failed to induce an 
adequate anti-tumor response in poorly immunogenic tumors. 
Therefore, OX40 antibodies will probably be developed in combi-
nation with inhibitory antibodies such as anti-PD-1 or anti- 
CTLA-4.
The glucocorticoid-induced TNF receptor (TNFR)-related pro-
tein (GITR, CD357) is expressed at low levels on resting CD4+ and 
CD8+ T cells and is upregulated after TCR engagement. GITR is 
constitutively expressed on Tregs, resulting in an inhibitory func-
tion of Tregs. The GITR ligand (GITRL) is expressed on activated 
APCs and endothelial cells.
In preclinical models, agonistic GITR antibodies have induced 
lineage instability in Tregs and have shown costimulatory effects 
on effector T cells. In such models, impressive tumor responses 
have been observed, although it is unclear whether the costimula-
tory effects on T cells or the effect on the environment are respon-
sible for these responses. Preclinical model systems with CRC have 
also shown impressive effects of GITR antibody in combination 
with CTLA-4 blockade. Ongoing trials with agonistic GITR anti-
bodies as monotherapy or combination treatment with PD-1 anti-
body are ongoing, and are also recruiting CRC patients.
4-1BB (CD137) is a member of the TNFR superfamily and is 
known as a costimulatory receptor induced after T cell recognition. 
Binding of the 4-1BB ligand 4-1BBL induces T cell growth and dif-
ferentiation. 4-1BB is expressed at low levels on most cells of the 
hematopoietic system. Agonistic 4-1BB antibody will have effects 
on many different immune cell subsets. In preclinical models with 
CRC, responses of agonistic monoclonal 4-1BB antibodies have 
been observed. 2 monoclonal antibodies have been tested in clini-
cal trials showing acceptable toxicity and significant increase in ac-
tivated circulating T cells. Recently, a phase II trial with urelumab 
in melanoma was stopped after fatal liver toxicity. The other 4-1BB 
antibody PF-05082566 did not show significant toxicity in early tri-
als and is being developed in combination with antibody-depend-
ent cellular cytotoxicity-inducing monoclonal antibodies such as 
cetuximab and in combination with PD-1 blockade such as 
nivolumab. 
CD40, again a member of the TNFR superfamily, was detected 
on B cells and found to be expressed on DCs, monocytes, platelets 
and macrophage populations. There is also expression in fibro-
blasts, endothelial and epithelial cells. The CD40 ligand (CD40L) is 
expressed by activated T cells, B cells, and platelets. CD40 activa-
tion leads to enhanced antigen presentation, expression of costim-
ulatory molecules and maturation of DCs, which triggers T cell ac-
tivation. It was shown that CD40 is expressed in CRC cells, and 
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similar expression patterns were identified for CD40L expression 
[16]. There are currently 5 different agonistic monoclonal antibod-
ies with different affinities and Fc-fragments in early phase clinical 
testing. Since response rates in monotherapy were low, combina-
tion treatments with checkpoint inhibitors or chemotherapy are 
being developed clinically.
CD70, another member of the TNFR superfamily, is expressed 
on T and B cells. Expression on tumor cells has also been described. 
CD27-CD70 interaction can lead to immune escape by inducing 
apoptosis in T cells, inducing T cell exhaustion and supporting 
Treg function. Expression levels of CD70 in CRC are reported to 
be not that frequent, therefore clinical development of anti CD70 
antibodies will focus on other solid tumor types and hematological 
indications.
An agonistic CD27 antibody is being tested clinically in mono-
therapy and combination treatment. Objective responses in CRC 
have been reported.
Specific Situation in CRC
With the exception of MSI high CRC, all strategies using the ap-
proved checkpoint inhibitors and/or combination strategies with 
newer generation agonistic or antagonistic checkpoint molecules 
have more or less failed to produce impressive results in early 
phase trials in CRC. There are several potential reasons for this. 
Firstly, MSS CRC is a poorly immunogenic tumor with no or low 
preexisting immunity, and T cell immunity does not play a signifi-
cant role. Therefore, checkpoint molecules aiming at enhancing 
immunity are not effective.
What argue against this hypothesis are the findings from Galon 
et al., Halama et al. and others that clearly demonstrate that T cells 
play a highly significant prognostic role in primary CRC and repre-
sent the strongest predictive parameter in metastatic disease for 
chemotherapy response. Also, the mutational landscape shows rel-
evant frequencies of mutations in CRC compared to other tumor 
entities.
Secondly, the local tumor environment in metastatic MSS CRC 
is highly immunosuppressive and inhibits influx of activated T 
cells. Although treatment-naive patients with metastatic disease 
CRC do have T cell infiltrates at the tumor site, all T cells seem to 
be trapped at the invasive margin (fig.  1). A simple activation of 
such infiltrating T cells will not lead to a meaningful anti-tumor 
response without modulating the environmental factors that keep 
the T cells outside of the tumor lesion.
Our group has analyzed the tumor environment in more detail, 
looking at immune cell densities and their spatial distribution as 
well as at cytokine/chemokine concentrations in different areas of 
the local environment. The tumor stroma is rich in macrophages as 
the dominant type of immune cells, especially M2-polarized mac-
rophages [2, 17]. Several pathways that tumors use to create a T cell 
suppressive environment are activated. The CCL5/CCR5 axis 
seemed to be a potential target for modulating the tumor microen-
vironment (TME) into a more accessible milieu.
Preclinical human tissue models as well as a phase I clinical trial 
utilizing CCR5 inhibition induced a dramatic change of the environ-
ment towards a more T cell friendly environment, with redistribu-
tion of T cells, repolarization of M2 macrophages towards M1 mac-
rophages and regression of metastatic lesions in chemotherapy re-
fractory CRC patients [17]. This trial is the first to utilize repolariza-
tion of macrophages to modify the microenvironment and clearly 
shows the promising potential for this approach in CRC and other 
cancer entities. Based on these findings, a phase II trial testing the 
combination of CCR5 inhibition and pembrolizumab will start soon. 
In CRC, innovative immunotherapy approaches have to address 
the specific immunosuppressive composition of the TME in com-
bination with a T cell approach. Potential combination partners are 
drugs that specifically target the dominant suppressive cytokines/
chemokines of the environment (such as CCR5 blockade) and 
strategies that target dominant suppressive immune cell subtypes 
in the environment (e.g. chemotherapy, M2 targeting/depletion, 
radiotherapy or other immunomodulators). There is evidence 
from a phase II trial that combination treatment with atezolizumab 
plus FOLFOX plus Avastin in refractory disease leads to objective 
responses and high disease control rates (Bendell, ASCO GI 2015).
To explore this strategy further, we will start a clinical trial pro-
spectively testing the combination of atezolizumab plus FOLFOX 
plus Avastin in first-line metastatic CRC. The primary goal is to 
analyze the specific changes in the TME under treatment associ-
ated with response or resistance to treatment. Only if we under-
stand the complex regulation of the TME in CRC, we can intelli-
gently design combination treatments targeting the patient’s indi-
vidual suppressive elements leading to effective immune control. 
This strategy will change the conceptual design of clinical trials. 
Instead of giving the same treatment to the entire study popula-
tion, we treat different patients in the same trial differently (differ-
ent combinations, different sequences).
We rely on immunomonitoring platforms that allow us to get 
real-time information regarding the individual composition of the 
patient’s TME, including immune cell densities, their activation 
status and their spatial distribution as well as cytokine/chemokine 
concentrations in different tumor areas. 
Fig. 1. CD3 staining showing intense T cell infiltrates at the invasive margin 
in metastatic colorectal cancer.
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Companies are developing bispecific antibodies or bite mole-
cules that enrich cytokines such as IL-2 or IL-12 in tumors. Such 
molecules are also promising candidates for specific modulation of 
the environment.
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